- Conditions
- Graft Versus Host Disease, Acute
- Interventions
- CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs), Placebo, Corticosteroids
- Biological · Drug
- Lead sponsor
- Cynata Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Jacksonville, Florida + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 112
matching trials from the live ClinicalTrials.gov search.
- Conditions
- PSP - Progressive Supranuclear Palsy
- Interventions
- AADvac1, Matching Placebo
- Biological
- Lead sponsor
- Adam Boxer
- Other
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- COVID-19
- Interventions
- Placebo, Remdesivir, Risankizumab
- Other · Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Bakersfield, California • Newport Beach, California + 26 more
- Conditions
- COVID-19
- Interventions
- Niclosamide, Placebo, Telehealth monitoring
- Drug · Other
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Canakinumab, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 45 Years to 90 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Charlestown, Massachusetts • Stony Brook, New York
- Conditions
- Covid19
- Interventions
- Acebilustat, Placebo
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Hidradenitis Suppurativa
- Interventions
- CFZ533, Placebo to CFZ533, LYS006, Placebo to LYS006, MAS825, Placebo to MAS825, LOU064 25mg, LOU064 100mg, Placebo to LOU064, VAY736, Placebo to VAY736
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 8
- States / cities
- Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more
- Conditions
- Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
- Interventions
- IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care
- Drug · Behavioral
- Lead sponsor
- Kanecia Obie Zimmerman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Drug Abuse, Substance Abuse
- Interventions
- quetiapine fumarate, Matched Placebo, Cognitive-behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Long COVID, Long COVID-19, Sleep Disturbance
- Interventions
- Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
- Drug · Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sedentary Behavior, Lack of Physical Activity, Physical Inactivity
- Interventions
- LADIES online intervention (R33 phase), LADIES online control (R33 phase)
- Behavioral
- Lead sponsor
- Gramercy Research Group
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Knightdale, North Carolina
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- SLS-005, Matching Placebo
- Drug
- Lead sponsor
- Merit E. Cudkowicz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Advanced Cancer
- Interventions
- Psilocybin 25 mgs, Niacin 100mg, Psychotherapy
- Drug · Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 21 Years to 100 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • New York, New York
- Conditions
- Covid19
- Interventions
- Apixaban 2.5 MG, Placebo
- Drug
- Lead sponsor
- Thomas L. Ortel
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 121
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 101 more
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more
- Conditions
- Healthy
- Interventions
- TARIS Placebo, Sham Procedure
- Device · Procedure
- Lead sponsor
- TARIS Biomedical, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- ABBV-142, Placebo for ABBV-142
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Kissimmee, Florida + 7 more
- Conditions
- Gout
- Interventions
- DYV700, Placebo, Colchicine 0.6 mg
- Drug
- Lead sponsor
- Dyve Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Poway, California
- Conditions
- Long COVID, Long COVID-19, Hypersomnia
- Interventions
- Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Well-being
- Interventions
- Happify
- Behavioral
- Lead sponsor
- Happify Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- NUZ-001, Matching placebo
- Drug
- Lead sponsor
- Merit E. Cudkowicz, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- COVID-19
- Interventions
- Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- E2814, Lecanemab, Matching Placebo (E2814)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Coronavirus, Covid19
- Interventions
- bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV), AZD7442 (IM), SNG001, Camostat, BMS-986414 + BMS-986413, SAB-185 (3,840 Units/kg), SAB-185 (10,240 Units/kg), CASIRIVIMAB + IMDEVIMAB, Placebo for Bamlanivimab 7000mg, Placebo for Bamlanivimab 700mg, Placebo for BRII-196+BRII-198, Placebo for SNG001, Placebo for Camostat, Placebo for SAB-185 (low dose), Placebo for BMS-986414 + BMS-986413, Placebo for AZD7442 (IV), Placebo for AZD7442 (IM), Placebo for SAB-185 (high dose), bamlanivimab 700mg
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 4,044 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 207
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more